Achieve Life Sciences (ACHV) Stock Forecast, Price Target & Predictions
ACHV Stock Forecast
Achieve Life Sciences stock forecast is as follows: an average price target of $9.50 (represents a 115.91% upside from ACHV’s last price of $4.40) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ACHV Price Target
The average price target for Achieve Life Sciences (ACHV) is $9.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $8.00. This represents a potential 115.91% upside from ACHV's last price of $4.40.
ACHV Analyst Ratings
According to 2 Wall Street analysts, Achieve Life Sciences's rating consensus is 'Buy'. The analyst rating breakdown for ACHV stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Achieve Life Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 13, 2024 | Francois Brisebois | Oppenheimer | $11.00 | $4.83 | 127.74% | 150.00% |
| Nov 16, 2022 | - | Maxim Group | $8.00 | $2.26 | 253.98% | 81.82% |
The latest Achieve Life Sciences stock forecast, released on May 13, 2024 by Francois Brisebois from Oppenheimer, set a price target of $11.00, which represents a 127.74% increase from the stock price at the time of the forecast ($4.83), and a 150.00% increase from ACHV last price ($4.40).
Achieve Life Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $11.00 |
| Last Closing Price | $4.40 | $4.40 | $4.40 |
| Upside/Downside | -100.00% | -100.00% | 150.00% |
In the current month, the average price target of Achieve Life Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Achieve Life Sciences's last price of $4.40. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 13, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Dec 12, 2023 | Oppenheimer | Outperform | Outperform | Hold |
| Nov 16, 2022 | Maxim Group | Buy | Buy | Hold |
Achieve Life Sciences's last stock rating was published by Oppenheimer on May 13, 2024. The company gave ACHV a "Outperform" rating, the same as its previous rate.
Achieve Life Sciences Financial Forecast
Achieve Life Sciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Dec 21 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | Mar 10 | Mar 07 | Mar 06 | Mar 04 | Mar 03 | Mar 02 | Mar 99 | Jun 98 | Mar 97 | Mar 96 | Dec 95 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $2.94M | $1.37M | $11.73M | $5.08M | $1.32M | $1.20M | $4.70M | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | $125.00K | $62.50K | $62.50K | $50.00K | $2.86M | $2.33M | $9.84M | $7.79M | $1.45M | $1.84M | $4.78M | $12.91M | $6.67M | $39.38K | $42.35K | $30.00K | $2.22M | $885.12K | $3.97M | $371.24K | $441.77K |
| High Forecast | - | - | - | - | - | - | - | $125.00K | $62.50K | $62.50K | $50.00K | $3.43M | $2.79M | $11.81M | $9.34M | $1.74M | $2.21M | $5.74M | $15.49M | $8.00M | $47.25K | $50.82K | $36.00K | $2.66M | $1.06M | $4.76M | $445.49K | $530.12K |
| Low Forecast | - | - | - | - | - | - | - | $125.00K | $62.50K | $62.50K | $50.00K | $2.29M | $1.86M | $7.87M | $6.23M | $1.16M | $1.47M | $3.83M | $10.33M | $5.34M | $31.50K | $33.88K | $24.00K | $1.77M | $708.10K | $3.17M | $296.99K | $353.41K |
| # Analysts | - | - | - | - | - | - | - | - | - | 5 | 6 | 12 | 10 | 16 | 17 | 16 | 16 | 14 | 11 | 12 | 16 | 10 | 12 | 7 | 8 | 16 | 9 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 0.59% | 1.19% | 0.65% | 0.91% | 0.65% | 0.98% | - | - | - | - | - | - | - | - | - | - |
Achieve Life Sciences's average Quarter revenue forecast for Dec 21 based on 6 analysts is $50.00K, with a low forecast of $50.00K, and a high forecast of $50.00K. ACHV's average Quarter revenue forecast represents a -98.30% decrease compared to the company's last Quarter revenue of $2.94M (Mar 16).
Achieve Life Sciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Dec 21 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | Mar 10 | Mar 07 | Mar 06 | Mar 04 | Mar 03 | Mar 02 | Mar 99 | Jun 98 | Mar 97 | Mar 96 | Dec 95 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | 5 | 6 | 12 | 10 | 16 | 17 | 16 | 16 | 14 | 11 | 12 | 16 | 10 | 12 | 7 | 8 | 16 | 9 | 10 |
| EBITDA | - | - | - | - | - | - | - | $-10.86M | $-12.54M | $-10.01M | $-7.09M | $-3.65M | $-4.47M | $-8.58M | $-6.65M | $-6.84M | $-3.03M | $-3.03M | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | $-3.55M | $-5.68M | $-6.93M | $-8.97M | $-7.44M | $-4.08M | $-3.08M | $-4.75M | $-7.20M | $-3.83M | $-2.81M | $-2.25M | $-1.38M | $-3.41M | $1.34M | $-4.15M | $-3.20M |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | $-2.84M | $-4.54M | $-5.55M | $-7.17M | $-5.95M | $-3.27M | $-2.47M | $-3.80M | $-5.76M | $-3.07M | $-2.25M | $-1.80M | $-1.11M | $-2.73M | $1.60M | $-3.32M | $-2.56M |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | $-4.25M | $-6.82M | $-8.32M | $-10.76M | $-8.92M | $-4.90M | $-3.70M | $-5.70M | $-8.64M | $-4.60M | $-3.37M | $-2.70M | $-1.66M | $-4.10M | $1.07M | $-4.98M | $-3.84M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 0.79% | 1.24% | 0.74% | 0.92% | 0.74% | 0.98% | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict ACHV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Achieve Life Sciences's previous annual EBITDA (undefined) of $NaN.
Achieve Life Sciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Dec 21 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | Mar 10 | Mar 07 | Mar 06 | Mar 04 | Mar 03 | Mar 02 | Mar 99 | Jun 98 | Mar 97 | Mar 96 | Dec 95 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | 5 | 6 | 12 | 10 | 16 | 17 | 16 | 16 | 14 | 11 | 12 | 16 | 10 | 12 | 7 | 8 | 16 | 9 | 10 |
| Net Income | - | - | - | - | - | - | - | $-10.99M | $-13.56M | $-10.87M | $-7.19M | $-2.98M | $-4.04M | $-9.34M | $-5.12M | $-8.22M | $-865.00K | $-3.06M | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-10.47M | $-10.30M | $-10.98M | $-10.18M | $-9.75M | $-9.33M | $-8.19M | $-32.49M | $-38.67M | $-27.85M | $-23.63M | $-3.60M | $-5.74M | $-6.98M | $-9.02M | $-7.46M | $-4.11M | $-3.10M | $-4.67M | $-7.40M | $-3.90M | $-2.94M | $-2.41M | $-1.80M | $-3.92M | $971.15K | $-4.34M | $-3.42M |
| High Forecast | $-10.47M | $-10.30M | $-10.98M | $-10.18M | $-9.75M | $-7.90M | $-8.19M | $-32.49M | $-38.67M | $-27.85M | $-23.63M | $-2.88M | $-4.59M | $-5.58M | $-7.22M | $-5.97M | $-3.29M | $-2.48M | $-3.74M | $-5.92M | $-3.12M | $-2.35M | $-1.93M | $-1.44M | $-3.14M | $1.17M | $-3.47M | $-2.74M |
| Low Forecast | $-10.47M | $-10.30M | $-10.98M | $-10.18M | $-9.75M | $-10.41M | $-8.19M | $-32.49M | $-38.67M | $-27.85M | $-23.63M | $-4.32M | $-6.89M | $-8.37M | $-10.83M | $-8.95M | $-4.93M | $-3.72M | $-5.60M | $-8.88M | $-4.68M | $-3.53M | $-2.89M | $-2.16M | $-4.70M | $776.92K | $-5.20M | $-4.11M |
| Surprise % | - | - | - | - | - | - | - | 0.34% | 0.35% | 0.39% | 0.30% | 0.83% | 0.70% | 1.34% | 0.57% | 1.10% | 0.21% | 0.99% | - | - | - | - | - | - | - | - | - | - |
Achieve Life Sciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ACHV's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Achieve Life Sciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Dec 21 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | Mar 10 | Mar 07 | Mar 06 | Mar 04 | Mar 03 | Mar 02 | Mar 99 | Jun 98 | Mar 97 | Mar 96 | Dec 95 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | 5 | 6 | 12 | 10 | 16 | 17 | 16 | 16 | 14 | 11 | 12 | 16 | 10 | 12 | 7 | 8 | 16 | 9 | 10 |
| SG&A | - | - | - | - | - | - | - | $2.25M | $2.77M | $2.87M | $2.61M | $2.30M | $2.70M | $2.76M | $2.50M | $1.74M | $1.57M | $1.35M | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | $2.23M | - | $2.23M | $3.37M | - | - | $1.37M | $2.86M | $2.46M | - | - | - | - | - | $856.90K | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | $2.68M | - | $2.67M | $4.04M | - | - | $1.65M | $3.43M | $2.96M | - | - | - | - | - | $1.03M | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | $1.79M | - | $1.78M | $2.70M | - | - | $1.10M | $2.29M | $1.97M | - | - | - | - | - | $685.52K | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.03% | - | 1.24% | 0.74% | - | - | 0.98% | - | - | - | - | - | - | - | - | - | - |
Achieve Life Sciences's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ACHV last annual SG&A of $2.25M (Dec 22).
Achieve Life Sciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Dec 21 | Mar 16 | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | Mar 10 | Mar 07 | Mar 06 | Mar 04 | Mar 03 | Mar 02 | Mar 99 | Jun 98 | Mar 97 | Mar 96 | Dec 95 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | 5 | 6 | 12 | 10 | 16 | 17 | 16 | 16 | 14 | 11 | 12 | 16 | 10 | 12 | 7 | 8 | 16 | 9 | 10 |
| EPS | - | - | - | - | - | - | - | $-0.81 | $-1.40 | $-1.13 | $-0.76 | $-219.94 | $-392.02 | $-1.40K | $-767.67 | $-1.77K | $-195.92 | $-1.06K | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.30 | $-0.30 | $-0.32 | $-0.30 | $-0.28 | $-0.27 | $-0.24 | $-0.95 | $-1.13 | $-0.81 | $-0.69 | $-12.46 | $-0.43 | $-44.00 | $-104.50 | $-87.78 | $-70.62 | $-54.64 | $-36.63 | $-42.90 | $-26.40 | $-34.10 | $-19.80 | $-33.00 | $-84.15 | $4.98 | $-27.40 | $-54.26 |
| High Forecast | $-0.30 | $-0.30 | $-0.32 | $-0.30 | $-0.28 | $-0.23 | $-0.24 | $-0.95 | $-1.13 | $-0.81 | $-0.69 | $-9.97 | $-0.35 | $-35.20 | $-83.60 | $-70.22 | $-56.50 | $-43.71 | $-29.30 | $-34.32 | $-21.12 | $-27.28 | $-15.84 | $-26.40 | $-67.32 | $5.97 | $-21.92 | $-43.41 |
| Low Forecast | $-0.30 | $-0.30 | $-0.32 | $-0.30 | $-0.28 | $-0.30 | $-0.24 | $-0.95 | $-1.13 | $-0.81 | $-0.69 | $-14.95 | $-0.52 | $-52.80 | $-125.40 | $-105.34 | $-84.74 | $-65.57 | $-43.96 | $-51.48 | $-31.68 | $-40.92 | $-23.76 | $-39.60 | $-100.98 | $3.98 | $-32.88 | $-65.11 |
| Surprise % | - | - | - | - | - | - | - | 0.86% | 1.24% | 1.39% | 1.10% | 17.65% | 911.67% | 31.74% | 7.35% | 20.12% | 2.77% | 19.45% | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Achieve Life Sciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ACHV previous annual EPS of $NaN (undefined).
Achieve Life Sciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.68 | $70.00 | 10194.12% | Buy |
| CHRS | Coherus BioSciences | $1.05 | $9.00 | 757.14% | Hold |
| SPRO | Spero Therapeutics | $1.34 | $10.00 | 646.27% | Buy |
| XFOR | X4 Pharmaceuticals | $0.70 | $3.67 | 424.29% | Buy |
| CTMX | CytomX Therapeutics | $1.19 | $5.77 | 384.87% | Buy |
| IMMX | Immix Biopharma | $1.78 | $7.00 | 293.26% | Buy |
| ITOS | iTeos Therapeutics | $11.59 | $37.67 | 225.02% | Buy |
| CNSP | CNS Pharmaceuticals | $0.16 | $0.50 | 212.50% | - |
| ABOS | Acumen Pharmaceuticals | $2.44 | $7.00 | 186.89% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.79 | $38.80 | 181.36% | Buy |
| INZY | Inozyme Pharma | $5.81 | $14.67 | 152.50% | Buy |
| TCRX | TScan Therapeutics | $5.54 | $12.00 | 116.61% | Buy |
| ACHV | Achieve Life Sciences | $4.40 | $9.50 | 115.91% | Buy |
| NXTC | NextCure | $1.40 | $3.00 | 114.29% | Buy |
| APLS | Apellis Pharmaceuticals | $35.63 | $75.38 | 111.56% | Buy |
| BOLT | Bolt Biotherapeutics | $0.62 | $1.00 | 61.29% | Hold |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
ACHV Forecast FAQ
Is Achieve Life Sciences a good buy?
Yes, according to 2 Wall Street analysts, Achieve Life Sciences (ACHV) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of ACHV's total ratings.
What is ACHV's price target?
Achieve Life Sciences (ACHV) average price target is $9.5 with a range of $8 to $11, implying a 115.91% from its last price of $4.4. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Achieve Life Sciences stock go up soon?
According to Wall Street analysts' prediction for ACHV stock, the company can go up by 115.91% (from the last price of $4.4 to the average price target of $9.5), up by 150.00% based on the highest stock price target, and up by 81.82% based on the lowest stock price target.
Can Achieve Life Sciences stock reach $7?
ACHV's average twelve months analyst stock price target of $9.5 supports the claim that Achieve Life Sciences can reach $7 in the near future.
What are Achieve Life Sciences's analysts' financial forecasts?
Achieve Life Sciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-27.269M (high $-25.832M, low $-28.346M), average SG&A $0 (high $0, low $0), and average EPS is $-0.795 (high $-0.753, low $-0.826). ACHV's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-41.926M (high $-41.926M, low $-41.926M), average SG&A $0 (high $0, low $0), and average EPS is $-1.222 (high $-1.222, low $-1.222).
Did the ACHV's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Mar 2016), Achieve Life Sciences's revenue was $2.94M, beating the average analysts' forecast of $2.86M by 2.88%. The company's EBITDA was $-3.651M, beating the average prediction of $-3.546M by 2.97%. Achieve Life Sciences's net income was $-2.982M, missing the average estimation of $-3.6M by -17.17%. The company's SG&A was $2.3M, beating the average forecast of $2.23M by 2.97%. Lastly, the company's EPS was $-220, beating the average prediction of $-12.46 by 1665.17%